Suzhou Ribo Life Science Co., Ltd.

HK$43.18As of Sun 8 Nov 2026, 12:00 UTC
HKEX:6938Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (17.59%)
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM —
Mkt cap HK$7.328B
ROIC (4.99%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$51
18.99%
(91.41%)
Hold 11|1|8|6|0
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.81
0.88
0.92
0.93
14.88%
17.29%
17.20%
23.89%
Revenue¥M
363.0
377.0
381.6
371.4
10.31%
11.79%
13.54%
5.93%
Peers (US$934.8M)
Cap (US$)
PE
925.5M
28.74x
Capital
TTM
5Y
10Y
Leveragex
0.944
(0.274)
(0.181)
EBIT/Intx
2.243
0.287
0.244
Own earn%
(17.05)
(6.91)
7.35
Sh yield%
28.07
47.62
47.25
Owners
Insiders/Inst%
11.45
83.22
Short interest%
4.09
SBC / revenue%
4.32
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
1
Op margin range%
7–12
$1 testx
—
Incr. ROIC%
18